Phrenno-F.12 (Olanzapine 12mg + Fluoxetine 25mg) 30 Capsules

Managing the severe depressive phases of manic depression demands a multi-targeted clinical approach. Phrenno-F.12 capsules offer a powerful, dual-mechanism therapeutic option designed specifically for the treatment of depression caused by Bipolar disorder. By bringing together two distinct classes of psychiatric medication into a single capsule, Phrenno-F.12 works to safely rebalance erratic brain chemistry, offering renewed hope and mood stability for patients navigating complex emotional lows.

• Synergistic Dual-Action Formula: Phrenno-F.12 utilizes the combined strength of Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) antidepressant, and Olanzapine, a proven antipsychotic drug. Together, they target multiple neural pathways simultaneously to provide more comprehensive relief than standard single-drug therapies.

• Targeted Bipolar Depression Relief: This specific formulation is highly indicated for managing the deep, debilitating depressive episodes associated with Bipolar disorder (commonly referred to as Manic Depression).

• Effective Strategy for Treatment Resistance: Finding the right psychiatric treatment can be a long journey. The Fluoxetine and Olanzapine combination found in Phrenno-F.12 is widely recognized as an essential intervention that is sometimes given after other standard medications have failed to work.

• Precise Strength Configuration: The F.12 variant offers the maximum-dose configuration of the Phrenno line, allowing healthcare providers to scale the Olanzapine component to 12mg alongside a steady 25mg baseline of Fluoxetine to best suit patients requiring robust clinical support.